On May 20, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment… Continue Reading
On May 8, KEI published KEI Briefing Note: 2026:4, Comments on SCCR/48/3, the March 18, 2026 version of the WIPO Broadcast Treaty Text. KEI-BN-2026-4
On Thursday, 21 May 2026, Knowledge Ecology International (KEI) will convene a side event entitled, “The future of the WHO EML and access to novel medical technologies”. The panel will take place in the Henry Dunant Room in the Henry… Continue Reading
On Monday afternoon, 4 May 2026, Knowledge Ecology International (KEI) delivered the following opening statement at the 36th session of the WIPO Committee on Development and Intellectual Property. For development, measures to address access to patented technologies are important, and… Continue Reading
These were my notes from KEI’s intervention on April 30, 2026. Thank you for the opportunity to provide comments. This morning, we received the latest version of the Annex. It was 7882 words and 17 pages long, with 450 brackets,… Continue Reading
KEI-CFIUS-Paramount-Global-22April2026 I. PETITION Knowledge Ecology International (KEI) respectfully petitions the Committee on Foreign Investment in the United States (“CFIUS” or the “Committee”), pursuant to Section 721 of the Defense Production Act of 1950, as amended (50 U.S.C. § 4565) and… Continue Reading
On April 20, 2026, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration” (91 FR 16205) to Perpetual Biosciences, Inc.… Continue Reading
On March 2, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention… Continue Reading
On Wednesday morning, 26 March 2026, Knowledge Ecology International (KEI) delivered the following oral intervention on the PABS Annex drawn from these notes. The onscreen text that the Secretariat just shared for the PABS Annex includes a number of references… Continue Reading
On Monday, 12 January 2026 a division bench of the Delhi High Court comprised of Justice Hari Shankar and Justice Om Prakash Shukla approved the sale of a biosmilar version of nivolumab, a cancer drug marketed by the firm Zydus… Continue Reading